NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Sparky277,

I am not sure about the movie but if you meant GBM instead of GMB, then yes this is the same disease.

As far as crossover patients go, they will do the best they can to quantify overall survival benefit differences between any patients that never did cross over to receive DCVax-L from SOC, those that received DCVax-L only at crossover from SOC, those that received regular treatment regimen only and those that received treatment and then crossed over to restart treatment. All treatments stop by the time 3 years have passed per protocol.

The recently announced Phase 2 combination trial looks to further quantify benefit of treatment alone vs treatment plus a checkpoint inhibitor in the recurrent GBM population that has not previously been treated with either checkpoint inhibitors or other immunotherapy like DCVax-L. The small size of this trial plus involvement from NIH makes me think it is for something like a label extension or confirmation of a very high probability effect. SOC is not being used as a comparator which is highly unusual in any trial utilizing a treatment that is not yet approved by any regulatory body. Best wishes.